ABSTRAa. Metabolism of propionate in human subjects was studied using bolus administration of l-'3C-propionate i.v. or orally. The study population consisted of five patients with propionic acidemia (PA), eight with methylmalonic acidemia (MMA, four responsive to vitamin BIZ), one each with multiple carboxylase deficiency and transcobalamin-I1 deficiency, and five healthy volunteers. Concentrations of I-I3C-propionate were measured in blood in three patients with PA, two with MMA, and two controls. Breath samples were obtained at intervals during 3 h after the dose, isotopic enrichment of I3CO2 was measured, and the cumulative percentage of recovery of I3C was calculated from the individual's predicted resting energy expenditure. Recovery of I3CO2 and half-time of I-I3C-propionate in PA were significantly less than normal. The same parameters in MMA were below normal, but significantly greater than in PA. Recovery of I3CO2 was well correlated with clinical severity in PA, but did not correlate in MMA. Differences between MMA and PA may indicate different distribution of propionate pools, differences in inducibility of residual enzyme activities, or an alternate pathway for decarboxylation of propionate available in MMA but not PA. Only one patient with PA demonstrated increased 13C02 production during biotin treatment. In a B12-responsive MMA patient, no differences were noted within 2 d of initiating treatment with BIZ, but there was an increase in I3CO2 production after 4 mo. Recovery of I3CO2 was normal in the patient with transcobalamin-I1 deficiency before and after treatment with vitamin B17. In the ~a t i e n t with muletiple carboxylase deficiency, 13C02 generation was nearly normal while he was receiving his maintenance dose of biotin, and was not significantly changed after 3 and 7 d without biotin treatment, despite a decrease of 30% in lymphocyte propionyl-CoA carboxylase activity. (Pediatr Res 30: [15][16][17][18][19][20][21][22]1991) 
' Present address: Department of Pediatrics and Child Health, Kurume University: Kurume, Japan. Abbreviations PCC, propionyl-CoA carboxylase PA, propionic acidemia MCD, multiple carboxylase deficiency MMA, methylmalonic acidemia TC-11, transcobalamin-I1 GCMS, gas chromatography-mass spectrometry SIM, selected ion monitoring APE, atom percent excess VCO~, rate of COz production REE, resting energy expenditure Disorders of propionate metabolism are potentially life-threatening conditions that present a considerable heterogeneity of clinical manifestations, particularly evident in the tolerance to protein and response to pharmacologic doses of biotin or vitamin B I 2 Propionyl-CoA in human metabolism arises from the amino acids isoleucine, valine, threonine, and methionine, and to lesser extents from cholesterol and odd-chain length fatty acids. An additional source is propionate-producing bacteria in the gut.
Propionyl-CoA is carboxylated by PCC, and the resulting smethylmalonyl-CoA is converted by methylmalonyl-CoA racemase to R-methylmalonyl-CoA, which is isomerized by methylmalonyl-CoA mutase to succinyl-CoA, which is then oxidized in the tricarboxylic acid cycle to yield C02. In human disease, this pathway may be blocked at either the PCC or mutase steps. PA may arise from a defective PCC apoenzyme or from deficient holoenzyme formation, as in MCD due to holocarboxylase synthetase or biotinidase deficiency. MMA may arise from an altered mutase apoenzyme, from disordered cobalamin metabolism, which may give rise to MMA alone or in conjunction with homocystinuria, or from B12 deficiency, including that arising from TC-I1 deficiency.
Vitamin BIZ can be lifesaving in certain complementation groups of MMA (I), and B12 is highly effective in TC-I1 deficiency (2). Treatment of MCD (3) and biotinidase deficiency (4) with biotin has been uniformly effective. There has been no evidence that patients with PA have improved clinically by treatment with biotin. However, reports that biotin treatment lowers the response of serum propionate concentrations to an isoleucine load ( 5 ) and increases cellular activity of PCC (6) provide an argument for testing the effects of biotin on each patient with PA. estimated oxidative rate can be of prognostic value. Our study was undertaken to explore the use of bolus administration of 1-I"-propionate as an adjunct in the evaluation of metabolic capacity in vivo, to compare the oxidation of propionate in patients with various defects of propionate metabolism, and to determine whether this methodology could be useful in evaluating vitamin responsiveness.
MATERIALS AND METHODS
Materials. Sodium l-13C-propionate (90 atom % I3C) was purchased from MSD Isotopes, Pointe Claire-Dorval, Quebec, Canada or (99 atom % 13C) was provided by Tracer Technologies, Somerville, MA. 2H6-propioni~ acid (98 atom % 2H) was purchased from KOR Isotopes, Cambridge, MA. Sodium propionate was obtained from Sigma Chemical Co., St. Louis, MO. Glassdistilled chloroform preserved with amylene was purchased from Burdick and Jackson Laboratories, Inc., Muskegon, MI; Bio-Sil A (200-400 mesh) silicic acid from Bio-Rad Laboratories, Richmond, CA; and Chromosorb 102 (60-80 mesh) for gas chromotography from Supelco, Bellefonte, PA. Twenty-mL evacuated tubes for collection of breath samples were non-silicon-coated Venoject tubes from Terumo Medical Corp., Elkton, MD.
Subjects. This research was approved by the University of California Human Subjects Committee, and informed consent was obtained from all patients or their parents. The patient population and sequence of tests are presented in Table 1 . The patients studied included five with PA and six with MMA, of which three were responsive to vitamin BI2. Unless otherwise indicated, biotin was administered at 10 mg/d orally, vitamin BI2 was given as 1 mg/d cyanocobalamin intramuscularly, and carnitine was given as 100 mg/kg orally, divided into two or three doses per day. All of the patients had not had an episode of acute acidosis for at least 1 mo before the studies, and all were well at the time of study, with two exceptions enumerated below. Patient L.S. developed a florid varicella eruption days after her first study and was convalescent at the time of the second study, while taking biotin. In one of the B12-responsive patients with MMA (S.H.), the first I3C-propionate breath tests were performed immediately before and 3 d after the initial trial of vitamin B12, but his course during the initial days of therapy was complicated by a febrile illness, and his urinary methylmalonic acid excretion increased from 19 to 92 ~m o l / m g creatinine despite the initiation of intramuscular cyanocobalamin. Subsequently, his responsiveness to B12 was evident and his diagnosis was confirmed by enzyme assay of cultured fibroblasts. He was tested again after 4 mo of ongoing oral cyanocobalamin therapy (1 mg/d), at which time he was in good health. One patient (A.F.) (3, 10) with MCD was studied who had a defective activity of holocarboxylase synthetase. His Km for biotin was higher than that of any of the other patients studied (3), and his clinical response to biotin was less complete than that of any of the other patients. He was studied while receiving 75 mg of biotin p.0. per day and at three and seven days after cessation of treatment with biotin. One patient with TC-I1 deficiency (M.W.) (2) was studied immediately before and after 1 mo of B,2 treatment, an interval over which her excretion of methylmalonate decreased from 13.3 to 0.14 Frnol/mg creatinine.
Standard metabolic analyses. Urinary organic acids were quantified by the method of Hoffmann et al. (1 I) . Lymphocyte carboxylase activities were assayed as previously described (12). Biotin in plasma and urine was determined immunochemically (Le TP, Sweetman L, Nyhan WL, unpublished data).
Studies of metabolism of sodium I-13C-propionate in vivo. Sodium 1-I3C-propionate was freshly dissolved in sterile water to make a 60 mmol/L solution, sterilized by filtration, and administered i.v. at 30 pmollkg or orally at 100 Frnol/kg body weight. The control individuals and the patients over the age of 3 were fasted overnight, and the other patients were fasted 3 h before the test; all were fasting during the tests. The subjects reclined in bed or engaged in quiet play throughout the period of collection of blood and breath samples. Blood samples of 3-5 mL were collected in acid citrate-dextrose solution for measurement of carboxylases in patients with PA or MCD. In six of the subjects, samples of heparinized blood (0.5 mL) were collected for determination of 1-"C-propionic acid before giving the isotope and at 5, 10, 15, 20, 30, 45, 60 , and 90 min after the isotope. The blood samples were placed on ice and then frozen at -20°C until analyzed. Two breath samples were obtained before the administration of the isotope and at 15-min intervals for 3 h after i.v. injection or 1, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150 , and 180 min after oral administration. Fifty mL of end-respiratory breath samples were collected in a syringe with a three-way stopcock from a Haldane tube in the older subjects and from a face mask in the younger subjects. The breath samples were transferred to duplicate evacuated tubes and kept at room temperature until analysis.
Measurement of I2C-and I3C-propionic acid in blood. The method of Bachmann et al. (13) for the quantitation of shortchain fatty acids in plasma by adsorption to silicic acid and elution with chloroform was modified by the use of an internal standard of 2H5-propionic acid and GCMS. To 0.4-mL samples of whole blood or plasma was added 25 pL of 2 pmol/L 2H6-propionic acid (98 atom % 2H) in 0.35 mol/L LiOH. The carboxy deuterium of 2H6-propionic acid exchanges with the large amount of water to give Li.2H5-propionate. The samples, containing 50 nmol of 2H5-propioni~ acid, were acidified to pH less than 1 with 25 pL of 6 M sulfuric acid, 1 g of Bio-Sil A was stirred in to give a free-flowing powder that was poured onto a 0.6-cm inner diameter X 15-cm glass column, and the column was filled with chloroform. Chloroform was pumped through the column at a flow rate of 2.5 mL/min for 6 min and the emuent was collected in vials containing 100 pL of 0.1 M LiOH in nanograde methanol. The alkaline effluent was evaporated in a stream of nitrogen to a small volume and transferred to 1.5-mL snap-cap conical tubes by rinsing with methanol, and the samples were dried completely in nitrogen, capped, and stored at -20°C. For analysis by GCMS, the samples were dissolved in 50 pL of 0.6 M HCl. Blank samples of distilled water were carried through the entire procedure to obtain corrections for the small amount of propionic acid in Bio-Sil A and chloroform.
Standards for GCMS were prepared that contained 0 to 250 nmol of sodium propionate (90 atom % I3C) and 50 nmol of Li. 2H5-propionate in 50 pL of 0.6 M HCl. A Finnigan (Sunnyvale, CA) model no. 402 1 gas chromatograph-mass spectrometer with an INCOS data system was used for (SIM) chemical ionization GCMS analysis of propionic acid, l-13C-propionic acid, and 'Hspropionic acid. Analyses were done on a GC column 2 mm inner diameter x 180 cm packed with Chromosorb 102 (60-80 mesh) with phosphoric acid-treated glass wool at the outlet end. The injector temperature was 200°C, the column temperature 180"C, and the direct transfer line to the MS source 280°C. The GC carrier gas was methane, which also served as the chemical ionization reagent gas, and the flow rate was 25 mL/min, with a pressure of 0.07-0.08 torr in the source. The ionizing voltage was 70 eV. Propionic acid eluted at about 5 min. For the injection of solutions of propionic acid, 1 pL of 0.6 M HCl was drawn into the syringe and then 2 pL of propionic acid in 0.6 M HC1. Between each sample 3 pL of 0.6 M HCl was injected twice to clean the column. The solvent fronts were diverted away from the source.
For SIM quantitation, the m/z were 75 for propionic acid, 76 for l-13C-propionic acid, and 80 for 2H5-propioni~ acid. The dwell time for each mass was 100 ms. Peak areas of the SIM chromatograms were calculated by the computer with the baseline points selected by the operator. For each day's analysis, standard curves for propionic acid and l-13C-propionic acid (90 atom % 13C) were determined. Linearity was excellent and the standard curve of the ratio of areas at m/z 75 to m/z 80 for I2C-propionic acid versus nmol of 2Hs-propionic acid was fitted by linear regression and used to calculate the concentration of I2C-propionic acid in the samples of blood. Similarly, the standard curve of the ratio of areas at m/z 76 to m/z 80 was used to calculate the concentration of '3C-propionic acid in the samples of blood. The experimentally determined natural abundance of '"-propionic acid was 2.70 atom %. The blood samples were analyzed and the atom % 13C-propionic acid was calculated as
(nmol "C-propionic acid)/(nmol "C-propionic acid + nmol 12C-propionic acid). APE I3C was obtained by subtracting the natural abundance. The l-13C-propionic acid injected in these studies was determined to be 89.8 atom % I3C. Measurement of1"02 in expired air. The '3C02/12C02 ratio in breath samples was measured by Tracer Technologies (Somerville, MA) using a VG-ISOGAS SIRA-10 ratio mass spectrometer. The APE of '"02 was derived from a comparison of ion currents at m/z 44, 45, and 46 (including correction for oxygen isotopes) relative to a standard sample (calibrated to Pee Dee Belemnite limestone). Access to an indirect calorimeter was not available throughout these studies, so each subject's endogenous Vco2 was estimated based upon predicted REE. The REE (kcal/h) was calculated using the Bateman formula and coeficients derived (14) to describe published (15) age-and sexdependent basal metabolic rates (kcal/m2. h) and an estimate of body surface area (BSA) based on weight and height according to the Dubois formula (16). Endogenous C 0 2 production was calculated from the REE assuming a RQ of 0.83 (L C02/L 02), a heat production of 4.83 kcal/L 0 2 (1 5), and a density of 44.6 mmol C02/L at 37°C and 1 atm. Because the basal metabolic rate (BMR) applies only under specific conditions (awake, supine, calm, postabsorptive) that are not always feasible during testing of subjects of the pediatric age group, an activity factor correction is desirable under these experimental conditions (sub-18 BARSHOP ET AL. jects engaged in sedentary activity). Based upon indirect calorimetry, energy expenditure in adult subjects confined to bed and out of bed ranges from 1.2 to 1.3 times the basal rate (17), and similar measurements in another series (18) yielded an activity factor of 1.23 k 0.08. Accordingly, we used an activity factor of 1.25 in the present study, and calculated Vco2 (mmol/min) as VCO~ = BMR/60 X BSA X (0.83 X 44.6)/4.83 X 1.25
The rate of 13C02 production is normalized to % dose/h, calculated as
To calculate the cumulative percent dose excreted, the area under the curve of APE versus t was numerically integrated with cubic splines, using algorithms of the International Mathematics and Statistics Library (Chicago, IL). The cumulative percent dose excreted at time t, CPD(t), is then CPD(t) = Vco2 x APE(t)/(mmol I3C administered) x 100 lt Calculated spline curves were also used to determine the maximum values for % dose/h and times of maxima, as presented below.
RESULTS
Concentrations of I-13C-propionate in blood and half-lives. Blood propionate concentrations were measured in three patients with PA, two with MMA, the patient with MCD, and two control subjects (Table 1) . Among the patients with PA, the concentrations of I2C-propionate in blood before administration of I3C-propionate were 2.5 to 100 times the mean control levels. The 19-to 41-fold lower concentrations in patient P.S. than in E.A. were considered to reflect an excellent level of control in a rigorously compliant family. The concentrations of propionate were between 5-fold and 16-fold above the control mean in L.S., the patient with somewhat milder manifestations of PA; however, the second value was obtained during resolution of a varicella infection. The blood propionate concentrations in C.H., a patient with classic MMA, were as high as typical values from patients with PA, whereas in J.B., the patient with much milder B12-unresponsive MMA, the concentrations were only approximately 2.5 times control.
The half-life of 13C-propionate was between 4 and 5 min in each of the three control experiments carried out. Virtually identical results were obtained in A.F., the patient with MCD. In the patients with PA, the values ranged from about 3 to 7 times greater than control. The half-times in the two patients with MMA were shorter than in PA, and that was true even when comparing patient C.H. to patient P.S., although C.H. had zero-time propionate concentrations 2.5 to 4 times greater than P.S. Pool sizes were estimated for the patients with vitaminunresponsive PA or MMA from the natural logarithm of APE "C-propionic acid extrapolated to zero time. Pool sizes were undefined in the control patients and the patient with MCD, because the extrapolated zero-time APE was greater than the APE of the infused I3C-propionic acid (reflecting the great excess of the bolus relative to the pool and the noninstantaneousness of infusion). Turnover of propionate in the patients, estimated from the pool sizes and slopes of the first-order curves, ranged from 0.41-4.98 pmol/min/kg. This is comparable to the values of 0.92-3.10 pmol/min/kg found for five patients with MMA studied with continuous infusion of labeled propionic acid (1 9).
Conversion of l-13C-propionate to I3CO2. The time course of isotopic enrichment of I3C in expired C 0 2 after i.v. and oral administration of 1-13C-propionate is shown in Figure 1 . In control individuals, the conversion to I3CO2 was rapid, with the greatest enrichment observed at 15 min or less after i.v. administration. There was very little difference between the time courses after i.v. or oral administration, although the maximum enrichment was slightly later when the tracer was given orally. There was very little generation of I3CO2 in patients with PA, and the curves were virtually flat. The I3CO2 enrichment curves in patients with MMA were flatter than those for control subjects, but there was significantly more generation of I3CO2 than there was in patients with PA. With only one exception (patient L.S. on biotin), the highest cumulative percent dose expired for any patient with PA was below the lowest value for any patient with MMA. The recovery of I3CO2 correlated negatively with clinical severity (9) in subjects with PA, as shown in Figure 2 . The regression coefficient of -0.849 was highly significant statistically. In contrast, the recovery of I3CO2 did not correlate with clinical severity of MMA. The results were indistinguishable from normal in the patient with TC-I1 deficiency before B12 treatment, at a time when she was excreting modest but distinctly abnormal quantities of methylmalonate.
Effects of biotin, vitamin B12, and carnitine. In the patients with PA whose blood propionate concentrations were measured, there appeared to be no real difference in the concentrations of propionate in the blood or in the half-life of 13C-propionate before and after treatment with biotin (Table I ). In L.S., the patient with somewhat milder PA, the concentration of propionate appeared to correlate with the status of her varicella rather than to be an effect of biotin. Nevertheless, the conversion of 1-I3C-propionate to 13C02 was increased in L.S. during biotin treatment (from 21.7 to 30.5% at 3 h), whereas in all of the other patients with PA there was no appreciable change in the extent of conversion with biotin. Also, among the patients with PA, the lymphocyte carboxylase activities increased only in L.S. after treatment with biotin (Table 2) .
In the two patients with BI2-unresponsive MMA whose blood propionate concentrations were studied, the half-life of propionate and the conversion of 1-I3C-propionate to I3CO2 were virtually identical in the presence and absence of vitamin B12 (Table 1 ). In the patients with apparent mitochondria1 cobalamin reductase deficiency, T.C., T.J., and C.F., who were first studied after 2 wk, 4 mo, and 10 y of oral cyanocobalamin treatment, respectively, the recoveries of I3CO2 were among the highest for patients with MMA. S.H. was the only patient with MMA with whom there was an opportunity to test I3CO2 production before and after initiation of vitamin B12 treatment. After 3 d of intramuscular cyanocobalamin, there was no improvement in his apparent 1-I3C-propionate oxidation, although that was a time when his course was complicated by a febrile illness. However, there appeared to be a modest increase in I3CO2 recovery and a distinct increase in maximum enrichment after 4 mo of treatment with oral cyanocobalamin.
In A.F., the patient with MCD, the half-time of blood 1-I3C-propionate at 5 and 7 d after cessation of biotin therapy approximated the control value. Similarly, the cumulative percent of I3CO2 formation at 180 min indicated that the overall metabolism of propionate in vivo did not change in 7 d without biotin. In contrast, the concentration of biotin in plasma and urine declined sharply during the period of study (Table 3 ). The halflife of the initial loss from the major biotin pool as measured in plasma or urine was 1.5 to 2 d. The plasma carboxylase activities were never normal. At the start, the values for PCC, 3-methylcrotonyl-CoA carboxylase, and pyruvate carboxylase were 16, 15, and 13%, respectively, compared to simultaneously measured controls. Furthermore, they did not change very much during the course of the study. By 7 d without biotin, the levels of PCC and 3-methylcrotonyl-CoA carboxylase were 13 and 16% of control, respectively. The activity of pyruvate carboxylase declined to a greater degree, to 7.4% of control on d 4 and to 5.0% on d 7. The levels of urinary organic acids were maintained at close to the initial levels, but there was a gradual increase in the urinary content of 3-methylcrotonylglycine, 3-hydroxyisovalerate, and methylcitrate. Upper panels show the enrichment in APE 13C measured in the breath samples. Lowerpanels show the calculated cumulative percentage of the isotope dose expired. Circles mark data from control subjects (subject 4 in i.v. study and subject 2 in oral study), squares from a subject with MMA (C.H.), and triangles from a subject with PA (P.S.). Fig. 2 . Correlation between I3CO2 recovery and clinical severity in PA and MMA. Clinical severity scores were tallied according to Walter et a/. (9) . Circles, patients with PA; squares, patients with MMA; and ,filled squares; patients with B12-responsive MMA during B12 treatment. For PA, slope m = -2.57, regression coefficient r = 0.849, and significancep = 0.00047; for MMA, rn = 0.033, r = 0.015, and p = 0.89.
Clinical Severity
Carnitine supplementation was without a consistent effect on the generation of 13C02 in any of the patients (Table 1) .
DISCUSSION
This study design provides an estimate of relative propionate oxidation with a minimum of bedside procedures, but there are certain considerations that limit the interpretation of the data, in particular the use of Vco2 predictions and the bolus adminis- t Sample and control frozen at -20°C for 6 wk before assay. All other assays performed within 48 h of collection.
tration of tracer. The unavailability of an indirect calorimeter dictated the requirement to predict Vco2 from anthropometric data. This introduces a certain amount of uncertainty in the estimated isotope recovery, and it is of particular concern in comparing the patients with control, inasmuch as the validity of the Bateman formula (15) has not been confirmed in subjects with these disorders and with these therapies, including low protein diets. There is less concern using these predictions in comparing patient groups or therapeutic regimens in individual patients. The omission of indirect calorimetry did make it pos- sible to perform some of these studies at locations remote from a major medical center. All previous studies of I3C-propionate metabolism in vivo in patients with disorders of propionate metabolism have used the method of continuous tracer infusion. The bolus method as used here has distinct advantages in terms of noninvasiveness and acceptance by patients' families. In principle, it also permits the resolution of processes with different kinetic constants. However, there are certain assumptions that affect the kinetic interpretation of bolus tracer studies and that are difficult to validate. These limitations have been well discussed (e.g. reference 20). Of particular concern are 1 ) the requirement that the tracer mix with the primary pool rapidly relative to its rate of metabolism, 2) the requirement that the product move from the metabolic site to the sampling site rapidly with respect to the time of the sampling, 3) the fact that the tracee pool size will affect the enrichment of tracer, and 4) the possibility that a bolus of a relatively large amount of substrate will induce or stimulate residual enzyme or enzymes of alternate pathways. Because the first two assumptions cannot be validated with the available data, this study cannot be used to estimate the actual rate of propionate oxidation. The observed rate of I3CO2 appearance includes undefined kinetic terms of substrate distribution and transport. Nevertheless, the recovery of I3C should provide an index of the relative efficiency of propionate utilization, inasmuch as tracer mixing and I3CO2 excretion are not slow in the 3-h time scale of sampling (manifest by the return of 13C02 enrichment to near baseline). It is assumed that the retention of I3CO3-in slowly exchanging pools (21), which could account for up to 25% of the generated 13C02 (22, 23) , is similar in all patient groups. The proportion of C 0 2 release in expired air does not appear to be affected by protein intake in the neonate (24) .
To address the effect of tracee pool size comprehensively will require more extensive blood propionate analyses than have been performed in this study to date. At least a part of the calculated decrease in I3C recovery in the patients with increased propionate pools may arise from the dilution of the tracer. However, the observed differences in recovery between the patients with MMA and PA, taken as groups, are not likely to arise from differences in pool sizes (e.g. compare patients P.S. and C.H. in Table 1 ). Furthermore, there is a distinct delay of the appearance of I3CO2 in PA patients with respect to MMA patients (Fig. 3) . Although pool size would affect isotope recovery (decrease the cumulative percent dose), it should not affect the kinetic constants (alter the time of maximum l3CO2 enrichment). Other possibilities to explain the differences between MMA and PA are that 1) the rates of tracer mixing and/or substrate ingress or product egress at the mitochondrion are different (unlikely), 2) residual methylmalonyl-CoA mutase but not PCC is inducible, or 3) an alternate pathway of propionate decarboxylation is operant under these conditions in MMA but not in PA. patients with PA were so flat compared to those for controls that it appears likely that a different process or alternate pathway for the oxidation of propionate is involved in these patients. Abnormal oxidation of propionate to expiratory C 0 2 was also observed in patients with pernicious anemia given 2-I4C-labeled propionate (25) , and the kinetics observed in that study suggested the presence of two pathways, one prominent in normal individuals and another slower process assumed to arise from the poxidation
